Osimertinib Effective in Egfr T790m-Positive Lung Cancer

Susan Mayor

DOI: https://doi.org/10.1016/s1470-2045(16)30654-4

2017-01-01

Abstract:Patients with EGFR-mutated advanced non-small-cell lung cancer (NSCLC) given osimertinib had longer progression-free survival (PFS) and were more likely to respond to treatment than those given platinum plus pemetrexed after first-line EGFR tyrosine kinase inhibitor (TKI) therapy, according to trial results.

What problem does this paper attempt to address?

Osimertinib or EGFR-TKIs/chemotherapy in Patients with EGFR-mutated Advanced Nonsmall Cell Lung Cancer

Lei Huang,Hao Huang,Xiaoping Zhou,Jinfeng Liu,Chunrong Li,Min Fang,Junrong Wu

DOI: https://doi.org/10.1097/md.0000000000017705

IF: 1.6

2019-01-01

Medicine

Abstract:Background: The aim of this meta-analysis is to investigate the impact of Osimertinib on treatment efficacy in advanced nonsmall cell lung cancer (NSCLC). Methods: Trials comparing Osimertinib against epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)/chemotherapy in patients with NSCLC with an epidermal growth factor receptor (EGFR) mutation were included, and the pooled data for progression-free survival (PFS), overall survival (OS), overall response rate (ORR), disease control rate (DCR), and adverse events (AEs) were analyzed. Results: Analysis results based on 6 eligible trials showed that Osimertinib significantly improved the overall PFS (hazard ratio [HR] = 0.38, 95% confidence interval [CI] = 0.29–0.50), improved the OS (HR = 0.66, 95% CI = 0.48–0.89), increased the ORR (odds ratio [OR] = 1.76, 95% CI = 1.14–2.72), increased the overall DCR (OR = 1.18, 95% CI = 1.02–1.37), and reduced the grade 3 or greater AEs (relative ratio [RR] = 0.50, 95% CI = 0.33–0.75) in all subgroups except in the ORR in the Exon 19 deletion (Ex19del) and/or L858R subgroup. Compared to patients with Ex19del and/or L858R mutation, patients with the T790M mutation had the benefits of a greater PFS (41.7%), a greater ORR (80.0%), a greater DCR (71.2%), and fewer grade 3 or greater AEs (70.7%) (each P < .05). Race, sex, age, EGFR mutation, and smoking history may significantly predict additional benefits from Osimertinib, but there were no significant differences between subgroups stratified by these clinical characteristics. Conclusions: Osimertinib showed greater treatment benefit for patients with NSCLC with EGFR mutation than EGFR-TKIs/chemotherapy, especially for T790M mutation-positive patients.
Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment

Po-Lan Su,Jeng-Shiuan Tsai,Szu-Chun Yang,Yi-Lin Wu,Yau-Lin Tseng,Chao-Chun Chang,Yi-Ting Yen,Chia-Ying Lin,Chien-Chung Lin,Chin-Chou Wang,Meng-Chih Lin,Wu-Chou Su

DOI: https://doi.org/10.1016/j.lungcan.2021.06.014

IF: 6.081

2021-08-01

Lung Cancer

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objectives</h3><p>Osimertinib is the main treatment choice for pretreated patients with advanced non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) <em>T790M</em> mutations. However, the choice of subsequent therapy when progressive disease has developed after osimertinib treatment remains a major therapeutic challenge. This study evaluated the efficacy of osimertinib-based combination therapies in patients who developed progressive disease after treatment with osimertinib.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Material and methods</h3><p>We enrolled NSCLC patients harbouring <em>T790M</em> mutations pretreated with first- or second-generation EGFR tyrosine-kinase inhibitors and were receiving osimertinib at two tertiary referral centres between August 2015 and July 2019, and the subsequent treatment efficacy was assessed.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Osimertinib-based combination therapy yielded better overall survival (OS) than chemotherapy alone (not achieved vs. 7.8 months; hazard ratio, 0.39; 95 % confidence interval 0.17–0.89; P = 0.025) according to the Cox proportional hazards model adjusted for possible confounders. Synergism (combination index <1) between AZD9291 and chemotherapy and a higher proportion of apoptosis cells in combination treatment were also demonstrated in the T790M-positive PC9 cell line with acquired resistance to AZD9291.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>Our data supported the hypothesis that osimertinib-based combination therapy is associated with improved OS among patients with clinical progression following the use of osimertinib. These findings warrant further validation in a randomised controlled study.</p>

oncology,respiratory system
Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer

Gee-Chen Chang,Jin-Yuan Shih,Chong-Jen Yu,Heng-Sheng Chao,Cheng-Ta Yang,Chien-Chung Lin,Jen-Yu Hung,Sheng-Yen Hsiao,Chin-Chou Wang,Chih-Feng Chian,Te-Chun Hsia,Yuh-Min Chen

DOI: https://doi.org/10.1371/journal.pone.0303046

IF: 3.7

2024-05-16

PLoS ONE

Abstract:Osimertinib has demonstrated efficacy in patients with epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer (NSCLC) in clinical trials. However, real-world data on its effectiveness remain scarce. Taiwanese patients with T790M-positive locally advanced or metastatic NSCLC and progressive disease following treatment with at least one EGFR tyrosine kinase inhibitor (TKI) were enrolled from the osimertinib early access program. Of the 419 patients (mean age, 63 years; female, 67%), 53% were heavily pretreated (≥ third-line [3L]), making osimertinib a fourth-line (4L) intervention. The median progression-free survival (PFS) was 10.5 months (95% confidence interval [CI]: 8.95-11.41); the 18-month PFS rate was 26.5%. The median overall survival (OS) was 19.0 months (95% CI: 16.30-20.95); the 24-month OS rate was 40.9%. The objective response rate was 32.46%, and the disease control rate was 86.38%. The median time to treatment discontinuation of osimertinib monotherapy was 11.9 months (95% CI: 10.49-13.11). Subgroup analyses of median PFS and OS in the chemotherapy combination group vs. the osimertinib monotherapy group yielded no difference. Central nervous system (CNS) metastasis, number of prior lines of therapy, and types of initial EGFR-TKIs did not significantly impact outcomes. The median PFS values were 9.0 (95% CI: 5.18-11.34) and 10.9 (95% CI: 9.18-11.90) months with and without CNS metastasis, respectively, and 10.8 (95% CI: 8.59-12.69), 13.6 (95% CI: 10.89-16.3), and 9.2 (95% CI: 7.8-10.62) months for second-line (2L), 3L, and ≥4L therapy, respectively. In patients who received osimertinib as 2L therapy, the median PFS values in response to prior afatinib, erlotinib and gefitinib treatment were 11.2 (95% CI: 4.85-4.79), 10.5 (95% CI: 8.59-20.26) and 8.7 (95% CI: 7.21-16.79) months, respectively. Overall, real-world data from Taiwan support the clinical benefits of osimertinib in EGFR T790M -positive NSCLC.
Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer

B van Veggel,J F Vilacha Madeira R Santos,S M S Hashemi,M S Paats,K Monkhorst,D A M Heideman,M Groves,T Radonic,E F Smit,E Schuuring,A J van der Wekken,A J de Langen

DOI: https://doi.org/10.1016/j.lungcan.2019.12.013

IF: 6.081

Lung Cancer

Abstract:Objectives: Epidermal growth factor receptor (EGFR) exon 20 insertions comprise 4-10 % of EGFR mutations in non-small cell lung cancer (NSCLC) and are associated with primary resistance to first and second generation EGFR tyrosine kinase inhibitors (TKIs). In vitro and preclinical animal studies have shown that osimertinib exerts antitumor activity against EGFR exon 20 mutation positive NSCLC. We report on a cohort of advanced stage NSCLC patients who harbor an EGFR exon 20 mutation and received osimertinib treatment. Material and methods: Twenty-one patients were treated with osimertinib 80 or 160 mg once daily from April 2016 to June 2018, in four institutions in the Netherlands. Data were obtained retrospectively. Progression free survival (PFS), disease control rate (DCR), overall survival (OS) and objective response rate (ORR) were assessed using RECIST v1.1. Results: Thirteen patients received prior platinum-based chemotherapy, and three patients a first - or second generation EGFR TKI. We observed 1 partial response, 17 patients with stable disease and 3 with progressive disease as best response to osimertinib (ORR 5 %). Median PFS was 3.6 (95 % CI, 2.6-4.5) months. PFS did not differ for patients with co-occurring TP53 mutations (p = 0.937). The DCR at three months was 71 %. Median OS was 8.7 (95 % CI, 1.1-16.4) months. Conclusion: Osimertinib has limited antitumor activity in patients with EGFR exon 20 mutated NSCLC, with an ORR of 5 %.
Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer

Joan Rou-En Choo,Chee-Seng Tan,Ross A Soo

DOI: https://doi.org/10.1007/s11523-018-0554-5

Abstract:The treatment of lung cancer has changed dramatically with the development of tyrosine kinase inhibitors (TKIs) that target sensitizing somatic mutations of the epidermal growth factor receptor (EGFR). Despite remarkable initial responses, patients eventually develop progressive disease, with the most common cause of resistance to first-line EGFR TKIs being the acquired T790M mutation. Various third-generation EGFR TKIs have been developed to specifically target this acquired mutation, of which osimertinib is currently the only approved agent. In addition, the eagerly anticipated data from the FLAURA study recently found improved efficacy with increased progression-free survival (PFS) with osimertinib compared to standard of care first-generation EGFR TKIs in the first-line setting. Of note, osimertinib has also demonstrated promising efficacy in patients with known brain metastases. However, as patients invariably develop resistance during treatment with osimertinib, most commonly with the development of triple mutated EGFR (sensitizing mutations/T790M/C797S), which is resistant to all existing EGFR TKIs, efforts are currently ongoing to develop new strategies or novel compounds to specifically target this resistance mechanism.
Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations

Chi-Han Chen,John Wen-Cheng Chang,Ching-Fu Chang,Chen-Yang Huang,Cheng-Ta Yang,Chih-Hsi Scott Kuo,Yueh-Fu Fang,Ping-Chih Hsu,Chiao-En Wu

DOI: https://doi.org/10.21873/anticanres.15697

Abstract:Background/aim: Afatinib is a standard treatment for patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. Osimertinib can overcome the treatment resistance-associated EGFR T790M mutation, and the sequence of afatinib followed by osimertinib is an effective therapeutic strategy for NSCLC patients. This study comprehensively evaluated the outcomes of sequential therapy following frontline afatinib and identified predictive factors for T790M mutation acquisition. Patients and methods: Data from patients with advanced NSCLC treated with frontline afatinib at a Taiwanese hospital group from June 2014 to March 2018 were retrospectively reviewed. The EGFR T790M mutation was detected by tissue sequencing or liquid biopsy. The patients' clinicopathological features were collected, and univariate and multivariate analyses were performed to identify potential predictive and prognostic factors. Results: A total of 635 patients treated with afatinib were enrolled in this study. Until August 2021, 553 patients experienced progression, and 225 patients underwent T790M mutation testing. The T790M positive rate was 54.2%. Both exon 19 deletion and progression-free survival were associated with T790M positivity. Osimertinib was found to be effective in T790M-positive but not T790M-negative NSCLC. The median overall survival (OS) was 61.8 months for patients with T790M mutation undergoing later-line osimertinib compared with 30.1 months for patients without T790M mutation undergoing chemotherapy only. Osimertinib independently prolonged OS after afatinib progression. Conclusion: This study confirmed the efficacy of sequential afatinib and osimertinib treatment. T790M mutation detection and osimertinib availability are important for prolonging survival in patients with NSCLC harboring EGFR mutations.
Osimertinib Efficacy and Safety in Treating Epidermal Growth Factor Receptor Mutation‐Positive Advanced Non–Small‐Cell Lung Cancer: A Meta‐Analysis

Mengmeng Zhao,Jian Zhang,Jie Gao,Jianping Wang,Zhenkai Ma

DOI: https://doi.org/10.1002/cpdd.1483

2024-11-10

Clinical Pharmacology in Drug Development

Abstract:This study compared the safety and efficacy of osimertinib, a third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), with those of other TKIs and its use alongside bevacizumab in patients with EGFR mutation‐positive advanced non–small‐cell lung cancer. PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang, and VIP databases were used to conduct extensive searches for relevant randomized controlled trials until January 30, 2024. Osimertinib monotherapy favored disease control rate, whereas the comparator treatment arm favored overall survival. Using subgroup analysis, the objective response rate and progression‐free survival (PFS) were significantly elevated by Osimertinib monotherapy compared with pemetrexed combined with carboplatin or cisplatin. The comparator treatment arm receiving gefitinib or erlotinib significantly favored progression‐free survival and overall survival compared with osimertinib monotherapy. In patients treated with osimertinib monotherapy, the incidence of all adverse events (AEs) decreased compared with comparator treatment arm. Anemia was the only AE associated with osimertinib monotherapy. Pemetrexed combined with carboplatin or cisplatin resulted in greater loss of appetite than osimertinib monotherapy. The most associated AE of osimertinib monotherapy was diarrhea, according to network analysis. Although its efficacy is not consistent with other EGFR TKIs, osimertinib was associated with a decrease in AEs in patients with EGFR mutation‐positive advanced non–small‐cell lung cancer.

pharmacology & pharmacy
Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations

Kelsey Pan,Jennifer Owens,Yasir Elamin,Charles Lu,Mark Routbort,Jianjun Zhang,Frank Fossella,Marcelo V Negrao,Mehmet Altan,Jenny Pozadzides,Ferdinandos Skoulidis,Anne Tsao,Tina Cascone,John V Heymach,Edwin Ostrin,Xiuning Le

DOI: https://doi.org/10.1016/j.jtho.2024.06.004

2024-06-10

Abstract:Introduction: Germline mutations driving lung cancer have been infrequently reported in the literature, with EGFR T790M being a known germline mutation identified in 1% of NSCLCs. Typically, a somatic EGFR mutation is acquired to develop lung adenocarcinoma. Osimertinib has become a standard-of-care treatment for EGFR T790M-positive lung cancer. Methods: We perform a retrospective analysis through the Lung Cancer Moon Shot GEMINI database at the University of Texas MD Anderson Cancer Center. Of the patients that underwent cell-free DNA analysis, germline mutations were identified by those with high variant allelic fraction approximating 50%, followed by further confirmation on genetic testing. Results: We identified 22 patients with germline EGFR mutations, with the majority harboring an EGFR T790M mutation (95.5%) and an EGFR L858R somatic mutation (50%). Notably, most patients were female (86.4%), non-smokers (81.8%), white (86.4%), had a family history of lung cancer (59.1%), and stage IV at diagnosis (72.7%). A distinct radiographic pattern of small multifocal ground-glass pulmonary nodules was observed in the majority of our cohort (72.7%). Among the 18 with advanced-stage NSCLC, 12 patients (66.7%) were treated with first-line osimertinib, demonstrating a median progression-free survival (PFS) of 16.9 months (95% confidence interval [CI]: 6.3-not reached [NR]). Others were treated with first-line afatinib (11.1%) or chemotherapy (22.2%). Among the 17 patients treated with osimertinib (in first or second-line), median PFS was 20.4 months (95% CI: 6.3-NR) and median overall survival was 82.0 months (95% CI: 28.4-NR). Conclusions: Based on our institutional cohort, NSCLC driven by EGFR germline mutations occurs more frequently in non-smoking, white females with multi-focal pulmonary nodules radiographically. Osimertinib for advanced germline EGFR-mutated NSCLC renders similar PFS compared to somatic T790M EGFR-mutated NSCLC.
Survival benefit of anlotinib in T790M‐positive non‐small‐cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study

Ya Chen,Hongyu Liu,Nana Hu,Yanan Wang,Zhengyu Yang,Junqiang Zhang,Baohui Han

DOI: https://doi.org/10.1002/cam4.6232

IF: 4.711

2023-07-01

Cancer Medicine

Abstract:Our study suggested that antiangiogenic‐based therapy might improve PFS and OS in EGFR‐mutant NSCLC patients with acquired resistance to osimertinib. Moreover, we also conducted preliminary in vitro assays to evaluate the efficacy of Anlotinib and in combination with osimertinib in EGFR T790M‐mutant osimertinib‐resistant NSCLC cell line H1975OR. Objectives Acquired resistance represents a bottleneck to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment in lung cancer. Our study aimed to explore the efficacy of antiangiogenic‐based therapy in osimertinib‐resistant NSCLC patients and assess the efficacy of anlotinib in vitro study. Methods Our multicenter study retrospectively collected 268 osimertinib‐resistant NSCLC patients with EGFR T790M mutation and explored the efficacy of anlotinib in patients and in vitro. Results PFS was significantly longer in the antiangiogenic‐based therapy group than in the immunotherapy group (HR: 0.71, p = 0.050) and the chemotherapy group (HR: 0.28, p = 0.001). Both the ORR and DCR of the antiangiogenic‐based group were higher than the immunotherapy group and the chemotherapy group. Subgroup analysis showed a trend of more benefits from the anlotinib‐based therapy than the bevacizumab‐based therapy in terms of PFS (HR: 0.63, p = 0.087) and OS (HR: 0.52, p = 0.063). In vitro assays verified that anlotinib alone or combined with osimertinib exerted potent cytotoxicity to T790M‐mutant H1975 cell line with acquired osimertinib resistance. Conclusions Our study suggested that antiangiogenic‐based therapy might improve PFS and OS in EGFR‐mutant NSCLC patients with acquired resistance to osimertinib. Moreover, anlotinib‐based therapy could be a promising effective treatment for this group of patients.

oncology
Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study

Akihiro Yoshimura,Tadaaki Yamada,Yusuke Okuma,Akito Fukuda,Satoshi Watanabe,Naoya Nishioka,Takayuki Takeda,Yusuke Chihara,Shinnosuke Takemoto,Taishi Harada,Osamu Hiranuma,Yukina Shirai,Akihiro Nishiyama,Seiji Yano,Yasuhiro Goto,Shinsuke Shiotsu,Kei Kunimasa,Yoshie Morimoto,Masahiro Iwasaku,Yoshiko Kaneko,Junji Uchino,Hirotsugu Kenmotsu,Toshiaki Takahashi,Koichi Takayama

DOI: https://doi.org/10.21037/tlcr-21-461

2021-08-01

Translational Lung Cancer Research

Abstract:BACKGROUND: Osimertinib monotherapy is currently the standard of care as a first-line treatment for patients harboring <i>epidermal growth factor receptor</i> (<i>EGFR</i>) mutations; however, some <i>EGFR</i>-mutated non-small cell lung cancer (NSCLC) patients exhibit primary resistance and an insufficient response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Elevated programmed death-ligand 1 (PD-L1) expression in tumors was reported as a negative predictive factor for outcomes of first- or second-generation EGFR-TKIs.METHODS: We prospectively assessed advanced NSCLC patients with <i>EGFR</i> mutations who were treated with osimertinib at 14 institutions in Japan between September 2019 and December 2020. Relationships between outcomes of osimertinib monotherapy and patients' characteristics were reviewed.RESULTS: Seventy-one patients who underwent the tumor PD-L1 test were enrolled. Multivariate analysis identified tumor PD-L1 expression as an independent predictor for progression-free survival (PFS) with osimertinib treatment (P=0.029). The objective-response and disease-control rates for osimertinib treatment were significantly lower in patients demonstrating elevated PD-L1 levels relative to those with low or negative PD-L1 level (P=0.043 and P=0.007, respectively). Furthermore, among patients treated with osimertinib, those with high PD-L1 levels exhibited shorter PFS relative to those with low plus negative PD-L1 level (median PFS: 5.0 <i>vs.</i> 17.4 months; P<0.001).CONCLUSIONS: Elevated tumor PD-L1 expression is associated with poor outcomes of osimertinib monotherapy in previously untreated advanced NSCLC patients with <i>EGFR</i> mutation. Further clinical trials are warranted to accumulate evidence demonstrating the effectiveness of combination therapy with osimertinib for <i>EGFR</i>-mutated advanced NSCLC patients with elevated tumor PD-L1 expression.TRIAL REGISTRATION: UMIN000043942.

oncology,respiratory system
1369P EGFR T790M Ctdna Abundance and TP53 Co-Mutation by Next Generation Sequencing Predicted Clinical Outcomes of Osimertinib in Non-Small Cell Lung Cancer Patients from a Real-World Study

T. Tian,X. Fu,W. Wang,L. Jiang,X. Liang,Z. Ruan,Y. Yao

DOI: https://doi.org/10.1016/j.annonc.2020.08.1683

IF: 51.769

2020-01-01

Annals of Oncology

Abstract:Osimertinib, the third-generation EGFR TKI, has been approved for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutation after acquired resistance to the first-or second-generation of EGFR TKIs. However, the factors affecting the degree and duration of response to osimertinib is elusive. In this study, we aim to investigate the factors related to T790M abundance in ctDNA by next generation sequencing (NGS), and to analyze the association between the efficacy of osimertinib and T790M abundance in ctDNA. The study compromised 23 advanced EGFR T790M-mutated NSCLC patients which was detected by NGS after acquired resistance to the first-generation EGFR TKIs. The association between EGFR T790M abundance in ctDNA and clinicalpathological characteristics was performed by student t test or one-way ANOVA. Osimertinib outcomes were evaluated by osimertinib-related progression-free survival (PFS). The survival curves were calculated by the Kaplan-Meier method and analyzed by the log-rank test. Prior icotinib treatment led to the highest T790M abundance, compared with gefitinib and erlotinib. Older patients (The mPFS were 8.00±0.00 and 14.00±2.91months for patients older and younger than 68 years old, HR=0.15, 95%CI: 0.03-0.87, log-rank P=0.034), high T790M abundance (The mPFS were 9.00±1.48 and 25.00±0.00months for ctDNA T790M <4.2% and ≥4.2%, HR=0.17, 95%CI: 0.02-1.38, log-rank P=0.049) and prior icotinib (mPFS for patients who took gefinitb, erlotinib and icotinib were 14.00±7.33, 8.00±2.96 and 23.00±0.00months, HR=0.77, 95%CI: 0.43-1.39, log-rank P=0.014) were associated with improved osimertinib-related PFS. TP53 was the most common co-occurring mutations and led to shorter osimertinib-related PFS (mPFS for patients with or without TP53 co-mutation were 8.00±1.02 and 15.00±4.43months, HR=4.40, 95%CI: 0.82-23.49, log-rank P=0.042). T790M mutation abundance in ctDNA by NGS may be a novel method to predict the response and duration of osimertinib in the first-generation EGFR TKIs-resistant, T790M-mutated advanced NSCLC.
Three Novel EGFR Mutations (750_758del, I759S, T751_I759delinsS) in One Patient with Metastatic Non-Small Cell Lung Cancer Responding to Osimertinib: A Case Report

Huiying Li,Tingting Yu,Yongjuan Lin,Yu Xie,Jie Feng,Mingmin Huang,Aibin Guo,Xiangyu Liu,Zhenyu Yin

DOI: https://doi.org/10.2147/ott.s259616

IF: 4

2020-01-01

OncoTargets and Therapy

Abstract:Generations of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) can significantly improve the outcome of EGFR-positive NSCLC patients. However, acquired TKIs-resistant mutations are inevitable. Except the common EGFR alterations, more and more rare mutations are revealed by next-generation sequencing (NGS), the clinical significance of which are still unclear. Here, we report an advanced lung adenocarcinoma patient who harbored two novel EGFR exon 19 deletions (750_758del and I759S) at the beginning and exhibited a short response to icotinib for 7.0 months. Then, secondary resistance EGFR T751_I759delinsS occurred. Chemotherapy combined with bevacizumab and erlotinib was administered in turn but failed. Standard-dose osimertinib (80 mg daily) obtained durable clinical remission for 16 months, and high-dose osimertinib (160 mg daily) further prolonged the survival of 9 months after leptomeningeal metastases (LM) occurring. This study presented the first case of intractable terminal NSCLC in a patient with EGFR 750_758del, I759S and T751_I759delinsS mutations, who responded positively to osimertinib and achieved a prolonged OS of 52 months, providing a potential therapeutic option for the patients harboring these particular EGFR mutations.
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

David Planchard,Pasi A Jänne,Ying Cheng,James C-H Yang,Noriko Yanagitani,Sang-We Kim,Shunichi Sugawara,Yan Yu,Yun Fan,Sarayut L Geater,Konstantin Laktionov,Chee K Lee,Natalia Valdiviezo,Samreen Ahmed,Jean-Marc Maurel,Igor Andrasina,Jonathan Goldman,Dana Ghiorghiu,Yuri Rukazenkov,Alex Todd,Kunihiko Kobayashi,FLAURA2 Investigators,Juan Cundom,Karina Vera,Monica Casalnuovo,Marcelo Tatangelo,Nicolas Castagneris,Guillermo Streich,Chee Khoon Lee,Paul Mitchell,Brett Hughes,Michael Boyer,Thomas John,Dainik Patel,Gustavo Pinto,Yeni Neron,Rivadavio Oliveira,Juliana de Menezes,Adilson Faccio,Glaucio Bertollo,Gilberto de Castro Jr,Otavio Gampel,Frances Shepherd,Doreen Ezeife,Randeep Sangha,Eugenia Loredo,Cristian Ibarra,Carlos Rojas,Patricio Yanez,Yi Hu,Baoshan Cao,Yuan Chen,Ye Wang,Jialei Wang,Yueyin Pan,Zhigang Han,Bo Shen,Qiming Wang,Meili Sun,Yu Yao,Huiqing Yu,Liyan Jiang,Wenxiu Yao,Jian Fang,Lin Wu,Jie Hu,Rong Wu,Jianya Zhou,Yijiang Huang,Laiyu Liu,Leona Koubkova,Juraj Kultan,Libor Havel,Jaromir Roubec,Maurice Perol,Xavier Quantin,Charlotte Domblides,Hari Goyal,Rohan Bhise,Sumit Goyal,Satheesh Thungappa,Bivas Biswas,Chetan Deshmukh,Hiroshi Kagamu,Yuichi Tambo,Yoshitaka Zenke,Kyoichi Okishio,Terufumi Kato,Kazumi Nishino,Isamu Okamoto,Satoshi Oizumi,Toshiaki Takahashi,Tetsuji Kawamura,Masahiro Seike,Takehito Shukuya,Shoichi Kuyama,Manuel Leiva,Alejandro Figueroa,Vanessa Bermudez,Renzo Alvarez Barreda,Annielyn Beryl Ong-Cornel,Jerry Tan Chun Bing,Rubi Li,May Sabando,Arthur Gregory Lui,Jandre Jomar Alipat,Guia Elena Imelda Ladrera,Nina Karaseva,Artem Poltoratskiy,Elena Matyushina,Evgeniy Fomin,Daniil Stroyakovskiy,Olga Mikheeva,Louis Dupper,Rapoport Bernardo,Myung-Ju Ahn,Ji-Youn Han,Ki Hyeong Lee,Tae Min Kim,Tsung-Ying Yang,Inn- Wen Chong,Po-Hao Feng,James Chih-Hsin Yang,Te-Chun Hsia,Sheng-Hao Lin,Chih-Bin Lin,Virote Sriuranpong,Sarayut Lucien Geater,Busyamas Chewaskulyong,Jarin Chindaprasirt,Thanyanan Reungwetwattana,Kunlatida Maneenil,Teerapat Ungtrakul,Riyaz Shah,Raffaele Califano,Carles Escriu,Huiqi Yang,Pasi Jänne,John Hamm,Ian Anderson,Ali Amjad,Raza Khan,Jhanelle Gray,Eric McGary,Lyudmila Bazhenova,Chao Huang,Anirudha Dasgupta,Ronald Natale,Timothy Burns,Tarek Mekhail,Alexandra Spira,Anthony Van Ho,Melissa Crawley,William Lawler,Anthony Nguyen,Lisa Wang,Xuan Dung Pham,Tho Tran,Quyen Le,Khiem Dang

DOI: https://doi.org/10.1056/NEJMoa2306434

2023-11-23

Abstract:Background: Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI-sensitizing and EGFR T790M resistance mutations. Evidence suggests that the addition of chemotherapy may extend the benefits of EGFR-TKI therapy. Methods: In this phase 3, international, open-label trial, we randomly assigned in a 1:1 ratio patients with EGFR-mutated (exon 19 deletion or L858R mutation) advanced non-small-cell lung cancer (NSCLC) who had not previously received treatment for advanced disease to receive osimertinib (80 mg once daily) with chemotherapy (pemetrexed [500 mg per square meter of body-surface area] plus either cisplatin [75 mg per square meter] or carboplatin [pharmacologically guided dose]) or to receive osimertinib monotherapy (80 mg once daily). The primary end point was investigator-assessed progression-free survival. Response and safety were also assessed. Results: A total of 557 patients underwent randomization. Investigator-assessed progression-free survival was significantly longer in the osimertinib-chemotherapy group than in the osimertinib group (hazard ratio for disease progression or death, 0.62; 95% confidence interval [CI], 0.49 to 0.79; P<0.001). At 24 months, 57% (95% CI, 50 to 63) of the patients in the osimertinib-chemotherapy group and 41% (95% CI, 35 to 47) of those in the osimertinib group were alive and progression-free. Progression-free survival as assessed according to blinded independent central review was consistent with the primary analysis (hazard ratio, 0.62; 95% CI, 0.48 to 0.80). An objective (complete or partial) response was observed in 83% of the patients in the osimertinib-chemotherapy group and in 76% of those in the osimertinib group; the median response duration was 24.0 months (95% CI, 20.9 to 27.8) and 15.3 months (95% CI, 12.7 to 19.4), respectively. The incidence of grade 3 or higher adverse events from any cause was higher with the combination than with monotherapy - a finding driven by known chemotherapy-related adverse events. The safety profile of osimertinib plus pemetrexed and a platinum-based agent was consistent with the established profiles of the individual agents. Conclusions: First-line treatment with osimertinib-chemotherapy led to significantly longer progression-free survival than osimertinib monotherapy among patients with EGFR-mutated advanced NSCLC. (Funded by AstraZeneca; FLAURA2 ClinicalTrials.gov number, NCT04035486.).
The efficacy and safety of osimertinib in patients with advanced EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled trials

Tang,X.,Li,W.

DOI: https://doi.org/10.1183/13993003.congress-2024.pa4756

IF: 24.3

2024-11-01

European Respiratory Journal

Abstract:Background: Osimertinib is the third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR-T790M resistance mutations. Methods: Databases including PubMed, Embase, Medline, Cochrane Library, Web of Science, and Google Scholar were searched from inception to June 22, 2023. Randomized controlled trials (RCTs) that reported the efficacy and safety of osimertinib versus other treatments (placebo, other EGFR-TKIs, chemotherapy, immunotherapy, surgery, etc.) in treating EGFR-mutated NSCLC were included for analysis. Results: Sixteen studies containing 4931 participants were finally included. Patients who received osimertinib had better results regarding mPFS, ORR, and DCR (all p<0.05) as compared with other treatments. Specifically, osimertinib had better benefits regarding mPFS, ORR, and DCR as compared with placebo, chemotherapy (Platinum-Pemetrexed), and docetaxel plus bevacizumab, respectively, and had better benefits inmPFS and DCR as compared with other EGFR TKIs(Gefitinib/Erlotinib). Conclusions: This meta-analysis suggests that osimertinib has a positive effect on survival and disease control for patients with EGFR-mutated NSCLCc compared with other treatments. Osimertinib had a superior effect when used in the second line and combination with chemotherapy, while its complications need more attention.

respiratory system
Benefits of osimertinib treat a lung adenocarcinoma patient with germline EGFR T790M, somatic EGFR 19-Del, TP53 and PIK3CA mutations

Yingxue Li,Guangqi Li,Zheng Zheng,Wenjuan Wen,Haihui Zhao,Xia Liu,Jiaping Xie,Lin Han

DOI: https://doi.org/10.1186/s13053-024-00286-4

2024-08-21

Hereditary Cancer in Clinical Practice

Abstract:Somatic mutations in the EGFR gene occur in about 50% of non-small cell lung cancers, with the T790M mutation significantly contributing to secondary resistance against EGFR -TKI drugs. However, EGFR T790M germline mutations rarely occur.

oncology
Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion

Yeon Joo Kim,Won Jun Ji,Jae-Cheol Lee,Sung-Min Chun,Chang-Min Choi

DOI: https://doi.org/10.4143/crt.2021.857

Abstract:Purpose: This study was to evaluate anti-tumor efficacy of osimertinib in patients positive for acquired epidermal growth factor receptor (EGFR) T790M mutation in liquid biopsy using plasma, bronchoalveolar lavage fluid (BALF) or bronchial washing fluid (BWF), and pleural effusion. Materials and methods: Among patients benefited from previous EGFR‒tyrosine kinase inhibitor treatment followed by treatment failure, patients in whom T790M mutations are detected in at least one of the samples including tumor tissues, BALF/BWF, plasma, and pleural effusion were enrolled. T790M mutation was detected by extracting cell free DNA from liquid biopsy samples, using PANA Mutyper. Objective response rate (ORR) and progression-free survival (PFS) with osimertinib treatment were evaluated. Results: Between January 2018 and December 2019, 63 patients were enrolled and received osimertinib. Mean age was 63 years, and 38 (60.3%) were female. Twenty-six patients had T790M mutation in both liquid and tissue samples (group A), 19 patients had only in tissue biopsy samples (group B), and 18 patients had T790M mutation only in liquid biopsy samples (group C). ORR in overall population was 63.5%, and was 61.5% in group A, 68.4% in group B, and 61.1% in group C, respectively. Median PFS in overall patients was 15.6 months (95% confidence interval, 10.7 to 24.2). There was no significant difference in ORR or PFS between groups. Conclusion: Osimertinib showed favorable efficacy in lung cancer patients with acquired resistance to prior EGFR-TKI therapies, who screened positive for harboring T790M mutation detected from cell free DNA extracted from plasma, BALF/BWF, and pleural effusion.
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

Masahiro Tsuboi,Roy S. Herbst,Thomas John,Terufumi Kato,Margarita Majem,Christian Grohé,Jie Wang,Jonathan W. Goldman,Shun Lu,Filippo de Marinis,Frances A. Shepherd,Ki Hyeong Lee,Nhieu Thi Le,Arunee Dechaphunkul,Dariusz Kowalski,Laura Bonanno,Manuel Dómine,Lynne Poole,Ana Bolanos,Yuri Rukazenkov,Yi-Long Wu

DOI: https://doi.org/10.1007/s11523-024-01034-3

2024-03-12

Targeted Oncology

Abstract:This is a summary of the original article "Overall survival with osimertinib in resected EGFR-mutated NSCLC.ˮ Osimertinib blocks the activity of the epidermal growth factor receptor (EGFR) on cancer cells, causing cancer cell death and tumor shrinkage, and is an effective treatment for EGFR-mutated non-small cell lung cancer (NSCLC). The ADAURA study assessed the effects of osimertinib versus placebo in patients with EGFR-mutated (exon 19 deletion or L858R) early stage (IB–IIIA) NSCLC removed by surgery (resected). Previous results from ADAURA demonstrated that patients treated with osimertinib stayed alive and cancer-free (disease-free survival) significantly longer than patients who received placebo. Recent data showed the overall length of time patients were alive after starting treatment (overall survival). In both the primary stage II–IIIA and overall stage IB–IIIA populations, patients in the osimertinib group had a significant 51% reduction in the risk of death compared with the placebo group. The data demonstrated that osimertinib after surgery significantly improved overall survival in patients with resected, EGFR-mutated, stage IB–IIIA NSCLC.

oncology
EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib

Anna Buder,Maximilian J. Hochmair,Ulrike Setinek,Robert Pirker,Martin Filipits

DOI: https://doi.org/10.21037/tlcr.2020.03.02

2020-04-01

Translational Lung Cancer Research

Abstract:BACKGROUND: Osimertinib has become standard therapy of advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients and T790M-mediated resistance. We investigated the clinical utility of EGFR mutation tracking in plasma-based circulating tumor DNA (ctDNA) after start of osimertinib therapy in metastatic, EGFR-mutant NSCLC patients who had progressed on prior therapy with EGFR tyrosine kinase inhibitors (TKIs).METHODS: We enrolled 141 patients with advanced EGFR-mutated NSCLC who underwent second-line osimertinib treatment for T790M-positive disease. After initiation of osimertinib, we obtained plasma samples from 108 patients. Plasma ctDNA was tested for EGFR mutations by means of droplet digital PCR and was termed positive if any EGFR mutation was detected.RESULTS: Plasma ctDNA was detected in 58 of 108 (54%) patients after osimertinib initiation and was associated with poor progression-free survival (PFS) [hazard ratio (HR) 4.26, 95% confidence interval (CI): 2.55-7.10, P<0.0001] and overall survival (OS) (HR 3.23, 95% CI: 1.80-5.78, P<0.0001). In multivariable analysis, ctDNA status remained significantly associated with PFS and OS (HR 4.87, 95% CI: 2.81-8.44, P<0.0001; HR 3.49, 95% CI: 1.88-6.50, P<0.0001). Patients with persistence of activating EGFR mutations within eight weeks had shorter durations of PFS (HR 6.17, 95% CI: 3.03-12.56, P<0.0001) and OS (HR 4.83, 95% CI: 2.25-10.36, P<0.0001) than patients with total clearance of the activating EGFR mutation. Persistence of activating EGFR mutations in plasma ctDNA remained an independent predictor of poor PFS and OS in multivariable analyses.CONCLUSIONS: Patients with persistence of activating EGFR mutations in plasma ctDNA within eight weeks after osimertinib initiation have worse prognosis and may require the addition of chemotherapy or other treatments in order to achieve better outcome.

oncology,respiratory system
Durable Response to Osimertinib in a Chinese Patient with Metastatic Lung Adenocarcinoma Harboring a Rare EGFR L858R/D761Y Compound Mutation

Yajie Zhu,Jianning Tang,Xin Li,Tian Qin,Yang Wei

DOI: https://doi.org/10.2147/ott.s268593

IF: 4

2020-10-01

OncoTargets and Therapy

Abstract:Uncommon mutations account for 10-15% of epidermal growth factor receptor (<i>EGFR</i>) mutations in patients with non-small-cell lung cancer (NSCLC). However, in spite of the wealth of knowledge of the clinical significance and tyrosine kinase inhibitor (TKI) sensitivity of these mutations, acquisition of deeper insights is limited by the paucity of case reports and cohort studies of the exceptionally rare mutations, including compound mutations. In the present case, we describe the clinical efficacy of icotinib and osimertinib in a metastatic lung adenocarcinoma patient carrying a highly uncommon <i>EGFR</i> L858R/D761Y compound mutation. The progression-free survival (PFS) with osimertinib treatment was much longer than that with icotinib (19 mo vs 8.2 mo), and the overall survival (OS) has currently exceeded three years. To the best of our knowledge, this is the first report of durable osimertinib response in an NSCLC patient with a rare <i>EGFR</i> L858R/D761Y mutation.

oncology,biotechnology & applied microbiology
Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options

Georgia Gomatou,Nikolaos Syrigos,Elias Kotteas

DOI: https://doi.org/10.3390/cancers15030841

2023-01-30

Cancers

Abstract:The development of tyrosine kinase inhibitors (TKIs) targeting the mutant epidermal growth factor receptor (EGFR) protein initiated the success story of targeted therapies in non-small-cell lung cancer (NSCLC). Osimertinib, a third-generation EGFR-TKI, is currently indicated as first-line therapy in patients with NSCLC with sensitizing EGFR mutations, as second-line therapy in patients who present the resistance-associated mutation T790M after treatment with previous EGFR-TKIs, and as adjuvant therapy for patients with early stage resected NSCLC, harboring EGFR mutations. Despite durable responses in patients with advanced NSCLC, resistance to osimertinib, similar to other targeted therapies, inevitably develops. Understanding the mechanisms of resistance, including both EGFR-dependent and -independent molecular pathways, as well as their therapeutic potential, represents an unmet need in thoracic oncology. Interestingly, differential resistance mechanisms develop when osimertinib is administered in a first-line versus second-line setting, indicating the importance of selection pressure and clonal evolution of tumor cells. Standard therapeutic approaches after progression to osimertinib include other targeted therapies, when a targetable genetic alteration is detected, and cytotoxic chemotherapy with or without antiangiogenic and immunotherapeutic agents. Deciphering the when and how to use immunotherapeutic agents in EGFR-positive NSCLC is a current challenge in clinical lung cancer research. Emerging treatment options after progression to osimertinib involve combinations of different therapeutic approaches and novel EGFR-TKI inhibitors. Research should also be focused on the standardization of liquid biopsies in order to facilitate the monitoring of molecular alterations after progression to osimertinib.

oncology

Osimertinib Effective in Egfr T790m-Positive Lung Cancer

Osimertinib or EGFR-TKIs/chemotherapy in Patients with EGFR-mutated Advanced Nonsmall Cell Lung Cancer

Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment

Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer

Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer

Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer

Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations

Osimertinib Efficacy and Safety in Treating Epidermal Growth Factor Receptor Mutation‐Positive Advanced Non–Small‐Cell Lung Cancer: A Meta‐Analysis

Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations

Survival benefit of anlotinib in T790M‐positive non‐small‐cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study

Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study

1369P EGFR T790M Ctdna Abundance and TP53 Co-Mutation by Next Generation Sequencing Predicted Clinical Outcomes of Osimertinib in Non-Small Cell Lung Cancer Patients from a Real-World Study

Three Novel EGFR Mutations (750_758del, I759S, T751_I759delinsS) in One Patient with Metastatic Non-Small Cell Lung Cancer Responding to Osimertinib: A Case Report

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

The efficacy and safety of osimertinib in patients with advanced EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled trials

Benefits of osimertinib treat a lung adenocarcinoma patient with germline EGFR T790M, somatic EGFR 19-Del, TP53 and PIK3CA mutations

Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion

Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib

Durable Response to Osimertinib in a Chinese Patient with Metastatic Lung Adenocarcinoma Harboring a Rare EGFR L858R/D761Y Compound Mutation

Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options